No, the NIFS Test Does Not Detect 95–99% of All Genetic Variants Found by Invasive Testing — Here's What the Numbers Actually Mean
“The non-invasive foetal sequencing (NIFS) test identified 95-99% of genetic variants found by invasive methods like amniocentesis and chorionic villus sampling”
The argument in brief
Some sources claim non-invasive foetal sequencing (NIFS) detects 95–99% of the genetic variants found by amniocentesis or CVS. This is partially false. While NIFS achieves close to 99% sensitivity for Down syndrome specifically, its accuracy drops sharply for other conditions — and it cannot reliably detect the full range of variants that invasive methods can find at all.
Data: NEJM Bianchi et al. 2014; ACOG Practice Bulletin 2020
Why it spread
The desire for a safer alternative to amniocentesis is completely understandable — invasive procedures carry a small but real miscarriage risk. When a test comes along with genuinely stunning accuracy for the most feared condition, people naturally want that to mean it covers everything. The 99% figure for Down syndrome is real and got repeated widely, while the fine print about other conditions and the test's fundamental limitations as a screening tool quietly fell away.
The claim sounds reassuring: a simple blood test that catches nearly everything a needle into the womb would find, without the risk. But that framing misrepresents what the science actually shows, and the difference matters for real medical decisions.
NIFS — also called cfDNA or NIPT screening — works by analysing fragments of foetal DNA circulating in the mother's blood. For the most common chromosomal condition, trisomy 21 (Down syndrome), it genuinely is impressive. A landmark 2014 study by Bianchi et al. in the New England Journal of Medicine found sensitivity of 98.6% for trisomy 21. That is where the high figures come from. But sensitivity falls to around 91% for trisomy 18, roughly 79% for trisomy 13, and drops far lower for rarer conditions.
The bigger problem is scope, not just accuracy. Amniocentesis and CVS, combined with chromosomal microarray analysis, can detect submicroscopic deletions, duplications, and single-gene disorders. NIFS currently cannot reliably identify most of these. The UK's NHS NIPT evaluation and the American College of Medical Genetics both state clearly that NIFS is a screening tool, not a diagnostic one — it is not a replacement for invasive testing when a full picture is needed. For chromosomal microarray-level variants, published figures suggest cfDNA sensitivity is around 30%, not 95–99%.
To be fair to the strongest version of this claim: if you narrow the question to common trisomies only, the high sensitivity figures are real and well-supported. The problem is the word "variants" — it implies a breadth that the test simply does not cover. Kitzman et al. in the New England Journal of Medicine demonstrated proof-of-concept for broader foetal genome sequencing as far back as 2012, but that research explicitly did not claim uniform 95–99% detection across variant types.
This misinformation spreads because a genuinely impressive statistic — near-perfect detection of Down syndrome — gets quietly stretched to cover all genetic conditions. Headlines rarely explain the difference between a screening test and a diagnostic test, or between one trisomy and the full landscape of heritable disorders. If you are making decisions based on NIFS results, ask your clinician specifically what the test does and does not screen for. A negative result is not a clean bill of genetic health.
Sources
- New England Journal of Medicine - Kitzman et al. (2012)
Non-invasive fetal whole-genome sequencing achieved detection of de novo mutations and inherited variants, but sensitivity varied considerably by variant type. The study demonstrated proof-of-concept but did not claim 95-99% detection of all genetic variants found by invasive methods.
- ACOG Practice Bulletin on Cell-Free DNA Screening
Cell-free DNA (cfDNA) screening shows high sensitivity (>99%) for trisomy 21 specifically, but sensitivity drops significantly for other chromosomal abnormalities and is not equivalent to diagnostic testing via amniocentesis or CVS for the full range of genetic variants.
- Lo et al. - Nature Medicine (2010)
Fetal genome reconstruction from maternal plasma was demonstrated but with variable accuracy across different variant types; SNP detection was feasible but not uniformly at 95-99% sensitivity across all variant categories compared to invasive methods.
- Bianchi et al. - New England Journal of Medicine (2014)
cfDNA screening for common aneuploidies (trisomies 21, 18, 13) showed sensitivity of 98.6% for trisomy 21, but the test does not detect the full spectrum of chromosomal and single-gene variants identifiable by amniocentesis or CVS.
- UK National Screening Committee / NHS NIPT Evaluation
NIPT/NIFS has high sensitivity for common trisomies but is not a replacement for invasive diagnostic testing. The scope of detectable variants is substantially narrower than amniocentesis or CVS, which can detect chromosomal microarray-level and single-gene abnormalities.
- Gregg et al. - Genetics in Medicine (2016) - ACMG Statement
The American College of Medical Genetics clarified that cfDNA/NIFS is a screening test, not a diagnostic test, and does not identify the full range of genetic variants detectable by invasive methods. False negative and false positive rates vary by condition and fetal fraction.
Related debunks
- UnverifiableCan't Confirm or Deny: Bill Ritter's Claim About His Cancer Treatment Is Unverifiable — Not False
- UnverifiableNo Evidence Bill Ritter Has Been Diagnosed With Alzheimer's — The Claim Is Unverified
- UnverifiableYes, Whey, Soy, and Pea Proteins Really Can Leave a Bad Aftertaste — And Science Explains Why